Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview | 7 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics under Development by Companies | 8 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Products under Development by Companies | 12 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies Involved in Therapeutics Development | 13 | 7 |
| CSL Limited | 13 | 1 |
| GeNeuro SA | 14 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 15 | 1 |
| Octapharma AG | 16 | 1 |
| Pfizer Inc. | 17 | 1 |
| Shire Plc | 18 | 1 |
| Teijin Pharma Limited | 19 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Assessment | 20 | 9 |
| Assessment by Monotherapy Products | 20 | 1 |
| Assessment by Combination Products | 21 | 1 |
| Assessment by Target | 22 | 2 |
| Assessment by Mechanism of Action | 24 | 1 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 2 |
| Drug Profiles | 29 | 23 |
| (hyaluronidase (human) (recombinant) + immune globulin (human)) Drug Profile | 29 | 4 |
| fingolimod hydrochloride Drug Profile | 33 | 6 |
| GL-2045 Drug Profile | 39 | 1 |
| GNbAC-1 Drug Profile | 40 | 3 |
| immune globulin (human) Drug Profile | 43 | 3 |
| immune globulin (human) Drug Profile | 46 | 1 |
| immune globulin (human) Drug Profile | 47 | 4 |
| immune globulin (human) Drug Profile | 51 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Dormant Projects | 52 | 1 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Development Milestones | 53 | 4 |
| Featured News &Press Releases | 53 | 1 |
| Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder | 53 | 1 |
| Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy | 53 | 1 |
| Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen | 54 | 1 |
| Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy | 54 | 1 |
| May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy | 55 | 1 |
| Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP | 56 | 1 |
| Appendix | 57 | 2 |
| Methodology | 57 | 1 |
| Coverage | 57 | 1 |
| Secondary Research | 57 | 1 |
| Primary Research | 57 | 1 |
| Expert Panel Validation | 57 | 1 |
| Contact Us | 57 | 1 |
| Disclaimer | 58 | 1 |